Hologic, Inc. $HOLX Shares Bought by Vontobel Holding Ltd.

Vontobel Holding Ltd. increased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 0.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 39,793 shares of the medical equipment provider’s stock after purchasing an additional 318 shares during the quarter. Vontobel Holding Ltd.’s holdings in Hologic were worth $2,593,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Chung Wu Investment Group LLC purchased a new stake in shares of Hologic in the second quarter valued at approximately $26,000. Grimes & Company Inc. purchased a new position in Hologic during the second quarter valued at $207,000. 111 Capital lifted its holdings in Hologic by 129.1% during the second quarter. 111 Capital now owns 16,085 shares of the medical equipment provider’s stock valued at $1,048,000 after purchasing an additional 9,064 shares in the last quarter. Cromwell Holdings LLC lifted its holdings in Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 436 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Hologic by 9.2% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 33,089 shares of the medical equipment provider’s stock valued at $2,156,000 after purchasing an additional 2,784 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Performance

Shares of Hologic stock opened at $67.76 on Friday. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.39. The company has a market cap of $15.07 billion, a price-to-earnings ratio of 28.12, a PEG ratio of 2.32 and a beta of 0.63. The business’s 50 day moving average price is $67.15 and its 200 day moving average price is $63.32. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same period last year, the company earned $1.06 EPS. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, research analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Upgrades and Downgrades

HOLX has been the subject of several research analyst reports. Wall Street Zen downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Evercore ISI set a $78.00 price objective on Hologic and gave the stock an “outperform” rating in a research note on Tuesday. UBS Group lifted their price target on Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a research note on Thursday, July 31st. Morgan Stanley lifted their price target on Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 31st. Finally, Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and raised their price objective for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, Hologic currently has an average rating of “Moderate Buy” and a consensus target price of $80.15.

Insiders Place Their Bets

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the business’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the transaction, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.88% of the stock is owned by insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.